 Visit Bulgaria |
GSK, Theravance report completion of Relovair studies in COPD and asthma
Pharmaceutical Business Review GlaxoSmithKline (GSK) and Theravance have announced the completion of the phase III registration programme for the once-daily investigational medicine Relovair used to treat chronic obstructive pulmonary disease (COPD) and asthma. … GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies … Theravance Falls Most in 3 Years After Glaxo Drug Fails Glaxo on the slide after trials setback for asthma drug |
View full post on asthma – Google News